3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Prostatic Neoplasms
7
Ovarian Neoplasms
2
Breast Neoplasms
2
Triple Negative Breast Neoplasms
1
Sarcoma
1
Pancreatic Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Kidney Neoplasms
1
Colorectal Neoplasms
1
Breast Neoplasms, Male
1
Interventions
Filgrastim
13
Carboplatin
10
Cyclophosphamide
9
pembrolizumab
8
Radiosurgery
8
Ifosfamide
8
Magnetic Resonance Spectroscopy
7
Etoposide
7
Biopsy
7
Specimen Handling
6
Doxorubicin
6
X-Rays
5
Phantoms, Imaging
5
Peripheral Blood Stem Cell Transplantation
5
Paclitaxel
5
Granulocyte Colony-Stimulating Factor
5
Gemcitabine
5
Cisplatin
5
pazopanib
4
palbociclib
4
Thiotepa
4
Temozolomide
4
Radiotherapy
4
Nuclear Medicine Department, Hospital
4
Nivolumab
4
Mesna
4
Melphalan
4
Docetaxel
4
Busulfan
4
Blood Specimen Collection
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Sarcoma
×
Genetic Counseling
×
Genitourinary
×
Clear all
NCT05225428
2026-05-22
VERDI
Dana-Farber Cancer Institute
Phase NA
Recruiting
1,020 enrolled